ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH METRONOMIC CHEMOTHERAPY (MPEBEV REGIMEN) IN METASTATIC NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Correale, Pierpaolo
Botta, Cirino
Martellucci, Ignazio
Licchetta, Antonella
Migali, Cristina
Bestoso, Elena
Apollinari, Serena
Guglielmo, Annamaria
Rossi, Marcello
Addeo, Raffaele [2 ]
Luzzi, Luca [1 ]
Gotti, Giuseppe
Tagliaferri, Pierosandro [3 ]
机构：
[1] S Maria Alle Scotte Hosp, Thorac Surg Unit, Siena, Italy
[2] S Giovanni Di Dio Hosp, San Giovanni Rotondo, Italy
[3] Magna Graecia, Catanzaro, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; bevacizumab; metronomic-chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1237 / S1237
页数：1
相关论文
共 50 条
  • [1] Metronomic chemotherapy in non-small cell lung cancer
    Shu, Yefei
    Weng, Shanshan
    Zheng, Song
    ONCOLOGY LETTERS, 2020, 20 (06)
  • [2] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB IN HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL
    Li, Heyan
    Takayama, Koichi
    Shiraishi, Yoshimasa
    Wang, Shuo
    Furuyama, Kazuto
    Harada, Taishi
    Nakanishi, Yoichi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S462 - S462
  • [3] Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?
    Ettinger, DS
    ONCOLOGIST, 2002, 7 (03): : 226 - 233
  • [4] ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Correale, Pierpaolo
    Martellucci, Ignazio
    Pastina, Pierpaolo
    Botta, Ciri-No
    Martino, Elodia
    Mazza, Daniela
    Tagliafer-Ri, Pierosandro
    Pirtoli, Luigi
    Caraglia, Michele
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S607 - S608
  • [5] Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer
    Jones, Benjamin S.
    Jerome, Mary S.
    Miley, Deborah
    Jackson, Bradford E.
    DeShazo, Mollie R.
    Reddy, Vishnu V. B.
    Singh, Karan P.
    Brown, Olivia C.
    Robert, Francisco
    LUNG CANCER, 2017, 106 : 125 - 130
  • [6] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL
    Li, H.
    Takayama, K.
    Wang, S.
    Furuyama, K.
    Harada, T.
    Nakanishi, Y.
    RESPIROLOGY, 2012, 17 : 90 - 90
  • [7] Chemotherapy for metastatic non-small cell lung cancer
    Pérol, M
    Moro-Sibilot, D
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (06) : S131 - S136
  • [8] THE COMBINATION CHEMOTHERAPY OF GEMCITABINE, CARBOPLATIN AND BEVACIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Kim, Bong Seog
    Ahn, Young Mi
    Lee, Moon Hyung
    Suh, Kang Heum
    Nam, Seung-Hyun
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1158 - S1158
  • [9] Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer
    Du, Nan
    Zhao, Hui
    Wang, Haibin
    Li, Xiaosong
    Ma, Junxun
    Fan, Zhongyi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Combination chemotherapy with topotecan for non-small cell lung cancer
    Dowlati, A
    Levitan, N
    LUNG CANCER, 2003, 41 : S23 - S26
12345